title: Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib.
abstract: Vemurafenib is an inhibitor of BRAF and is used to treat patients with metastatic melanoma who carry a V600E BRAF mutation. Recently, four patients have been described in the literature who developed a neutrophilic panniculitis following treatment with a BRAF inhibitor. We present an additional case and review the clinical findings of the cases reported to date.
authors.affiliation: Department of Dermatology, University of Southern California, Los Angeles, CA 90033, USA. genekim@usc.edu
authors.forename: Gene H
authors.initials: GH
authors.lastname: Kim
authors.forename: Alan
authors.initials: A
authors.lastname: Levy
authors.forename: Goli
authors.initials: G
authors.lastname: Compoginis
mesh_terms: D019943:Amino Acid Substitution; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects*; D008545:Melanoma / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000473:pathology*; D008875:Middle Aged; D020125:Mutation, Missense; D009362:Neoplasm Metastasis; D015434:Panniculitis / Q000139:chemically induced* / Q000201:enzymology / Q000235:genetics / Q000473:pathology*; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics / Q000378:metabolism; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects*; D000077484:Vemurafenib
chemical_list: D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf